EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Nxera Pharma Co's Enterprise Value is €718.1 Mil.
Nxera Pharma Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-59.0 Mil. Therefore, Nxera Pharma Co's EV-to-FCF for today is -12.17.
The historical rank and industry rank for Nxera Pharma Co's EV-to-FCF or its related term are showing as below:
FRA:JSS'
s EV-to-FCF Range Over the Past 10 Years
Min: -10270.95 Med: 9.09 Max: 4059.52
Current: -12.4
During the past 13 years, the highest EV-to-FCF of Nxera Pharma Co was 4059.52. The lowest was -10270.95. And the median was 9.09.
FRA:JSS's EV-to-FCF is ranked worse than 100% of 332
companies
in the Biotechnology industry
Industry Median: 16.26
vs FRA:JSS: -12.40
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nxera Pharma Co's PE Ratio (TTM) for today is calculated as:
Nxera Pharma Co's share price for today is €5.10.
Nxera Pharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.779.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Nxera Pharma Co EV-to-FCF Related Terms
Nxera Pharma Co EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Nxera Pharma Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nxera Pharma Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nxera Pharma Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Nxera Pharma Co's EV-to-FCF falls into.
Nxera Pharma Co's current Enterprise Value is €718.1 Mil.
Nxera Pharma Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-59.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nxera Pharma Co (FRA:JSS) has a EV-to-FCF of -12.17 as of Jul. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Nxera Pharma Co and its competitors. According to the industry distribution chart, Nxera Pharma Co ranks #999999 out of 332 companies in the Biotechnology industry.
Is Nxera Pharma Co's EV-to-FCF too high?
Nxera Pharma Co's current EV-to-FCF is -12.17. Based on the distribution chart, Nxera Pharma Co ranks #999999 out of 332 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nxera Pharma Co has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Nxera Pharma Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nxera Pharma Co ranks #999999 out of 332 companies for EV-to-FCF. This places Nxera Pharma Co in the lower half of its industry. The industry median EV-to-FCF is 16.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.26, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Nxera Pharma Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nxera Pharma Co's current EV-to-FCF is -12.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nxera Pharma Co stock overvalued right now?
Nxera Pharma Co (FRA:JSS) has a current EV-to-FCF of -12.17. The stock's GF Value™ is €6.99, compared to a current price of €5.10 — trading 27% below its estimated fair value. The current EV-to-FCF is -12.17. Nxera Pharma Co's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Nxera Pharma Co (FRA:JSS), the current EV-to-FCF is -12.17 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nxera Pharma Co (FRA:JSS) Overvalued in 2026?
Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be undervalued.
The current stock price of €5.10 is trading 27% below its estimated GF Value™ of €6.99.
Key valuation signals for FRA:JSS:
EV-to-FCF: -12.17
GF Value™: €6.99 vs. price of €5.10 (27% below fair value)
No single metric tells the full story. See the FRA:JSS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
73GF Score
Get the complete analysis for FRA:JSS
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:JSS has been successfully added to your 
